Scienture stock surged 355% on the commercial launch of Arbli, the first FDA-approved liquid losartan, backed by extensive distribution deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback